Loss of heterozygosity at 3p24-p25 as a prognostic factor in breast cancer. 2000

S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, 1-396 Kusugi-cho, Nakahara-ku, Kawasaki, Japan.

Differences in clinical course and biological characteristics among breast cancers will probably be explained ultimately by variations in the pattern of genetic alterations among the many genes that can play roles in carcinogenesis. Loss of heterozygosity (LOH) of a particular chromosomal region in a tumor, which presumably indicates loss of a growth-regulating 'tumor-suppressor' gene in that region, may represent a useful marker for postoperative prognosis. In earlier work we observed LOH at chromosomal regions 3p14-p21 and/or 3p24-p25 in a large proportion of breast cancers. To examine whether allelic losses in either of those regions might correlate with postoperative survival, we tested tumors from a cohort of 504 breast cancer patients for allelic losses of microsatellite markers in the relevant portions of chromosome 3p. Five years postoperatively, patients whose tumors had undergone LOH at 3p24-p25 were found to have borne significantly higher risks of mortality than women whose tumors retained both alleles at that locus; i.e. the 5-year mortality rate was 22% among patients with losses at 3p24-p25 vs. 9% with retentions of heterozygosity at that locus (P=0.0014). These data indicate that LOH at 3p24-p25 is a significant predictive factor for postoperative survival of patients who have undergone surgery for breast cancer.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002893 Chromosomes, Human, Pair 3 A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification. Chromosome 3
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D019656 Loss of Heterozygosity The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted. Allelic Loss,Heterozygosity, Loss of,Allelic Losses,Heterozygosity Loss

Related Publications

S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
May 2010, Cancer genetics and cytogenetics,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
April 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
April 2000, Nihon rinsho. Japanese journal of clinical medicine,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
December 1994, Cancer research,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
February 2005, World journal of gastroenterology,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
January 1997, British journal of cancer,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
October 1996, International journal of oncology,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
September 1995, British journal of cancer,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
May 2010, Breast cancer research and treatment,
S Matsumoto, and K Minobe, and Y Utada, and K Furukawa, and M Onda, and G Sakamoto, and F Kasumi, and Y Nakamura, and M Emi
March 1997, International journal of oncology,
Copied contents to your clipboard!